EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease

Tannaz Ranjbarian, Bernd Schnabl

Seminars in Liver Disease · 01.08.2023 · 43 (03) · 311-322

DOI: 10.1055/a-2145-7331 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, erschienen am 01.08.2023. Verfasst von Tannaz Ranjbarian und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California San Diego, La Jolla, California. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Liver Diseases, Alcoholic, Fatty Liver, Liver Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: National Institute on Alcohol Abuse and Alcoholism, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Globally, liver disease caused by alcohol is becoming more prevalent each year. Misuse of alcohol causes a spectrum of liver diseases, such as liver steatosis, steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. The cornerstone of treatment is abstinence from alcohol. In spite of this, available treatment for alcohol-associated liver disease (ALD) shows limited effectiveness currently. There are numerous ways in which alcohol disrupts the gut–liver axis, including dysbiosis of the gut microbiome, disruption of mucus and epithelial cell barriers, impaired production of antimicrobial molecules, and dysfunction of the immune system, causing translocation of viable microbes and microbial products to the liver and systemic circulation. Microbial exposure results in not only inflammation and progression of liver disease but also infections in late-stage ALD. This led scientists to focus their therapeutic strategies and targets for ALD on the gut microbiome. Throughout this review, we address the role of gut microbiome–centered therapeutic approaches for ALD focusing predominantly on randomized controlled trials. We will summarize the latest clinical trials using probiotics, antibiotics, and fecal microbial transplants in modulating the gut–liver axis and for improvement of ALD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeLiver Diseases, AlcoholicFatty LiverLiver NeoplasmsHumansLiverEthanolDysbiosis

Substanzen

Ethanol

Autor:innen und Institutionen

  • Department of Medicine, University of California San Diego, La Jolla, California.
  • Department of Medicine, VA San Diego Healthcare System, San Diego, California.

Förderung

  • National Institute on Alcohol Abuse and Alcoholism
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Ranjbarian, T., & Schnabl, B. (2023). Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease. Seminars in Liver Disease, 43(03), 311-322. https://doi.org/10.1055/a-2145-7331

Vancouver

Ranjbarian T, Schnabl B. Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease. Seminars in Liver Disease. 2023;43(03):311-322. doi:10.1055/a-2145-7331

BibTeX
@article{Ranjbarian2023,
  author = {Ranjbarian, Tannaz and Schnabl, Bernd},
  title = {Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease},
  journal = {Seminars in Liver Disease},
  year = {2023},
  volume = {43},
  number = {03},
  pages = {311--322},
  doi = {10.1055/a-2145-7331}
}
Kostenlos starten →